Acute-on-chronic liver failure (ACLF) is one of the most severe clinical syndromes in patients with chronic liver disease, particularly cirrhosis, and is associated with extremely high short-term mortality. Emerging evidence indicates that ACLF is not merely the terminal aggravation of decompensated cirrhosis, but an independent disease state driven by systemic inflammation, multi-organ dysfunction, and immune dysregulation. Disruption of gut–liver axis homeostasis is regarded as a key upstream mechanism: portal hypertension, gut microbiota dysbiosis, and intestinal barrier dysfunction promote bacterial translocation and the entry of pathogen-associated molecular patterns (PAMPs) into the portal circulation, which subsequently activate hepatic innate immune responses through Toll-like receptors (TLRs) and amplify systemic inflammation. At the same time, innate immune cells such as monocytes, macrophages, and neutrophils become persistently hyperactivated, whereas adaptive immune cells including T cells and natural killer (NK) cells gradually develop functional exhaustion and immunosuppression, resulting in a unique immunopathological state characterized by the coexistence of “hyperinflammation” and “immune paralysis.” The Two-to-tango model provides a useful framework to explain the simultaneous occurrence of high infection rates, organ failure, and short-term mortality in ACLF. This review summarizes the evolution of the ACLF concept, gut–liver axis imbalance, amplification of systemic inflammation, and dysregulation of immune effector cells, and discusses potential therapeutic strategies based on gut–liver axis intervention and immune stratification, with the aim of providing insights for mechanistic research and precision treatment of ACLF.

Yu Wei, Tan Xiaoping. The role of immune effector cell dysregulation in acute and chronic liver failure and its upstream mechanism of the gut–liver axis. Frontiers in Medical Science Research (2026), Vol. 8, Issue 4: 50-60. https://doi.org/10.25236/FMSR.2026.080407.

[1] Hernaez R, Solà E, Moreau R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553.

[2] Dirchwolf M, Ruf A E. Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis[J]. World journal of hepatology, 2015, 7(16): 1974.

[3] Laleman W, Claria J, Van der Merwe S, et al. Systemic inflammation and acute‐on‐chronic liver failure: too much, not enough[J]. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018(1): 1027152.

[4] Verbeke L, Nevens F, Laleman W. Bench-to-beside review: acute-on-chronic liver failure-linking the gut, liver and systemic circulation[J]. Critical Care, 2011, 15(5): 233.

[5] Moreau R. Acute-on-chronic liver failure: a new syndrome in cirrhosis[J]. Clinical and molecular hepatology, 2016, 22(1): 1.

[6] Arroyo V, Moreau R, Jalan R, et al. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis[J]. Journal of hepatology, 2015, 62(1): S131-S143.

[7] McCoy M, Trebicka J. Acute-on-chronic liver failure: a global disease[J]. Gut, 2022, 71(1): 1-2.

[8] Kumar R, Mehta G, Jalan R. Acute-on-chronic liver failure[J]. Clinical Medicine, 2020, 20(5): 501-504.

[9] Schulz M S, Angeli P, Trebicka J. Acute and non‐acute decompensation of liver cirrhosis (47/130)[J]. Liver International, 2024, 45(3): e15861.

[10] Dhiman R K, Agrawal S, Gupta T, et al. Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome[J]. World journal of gastroenterology: WJG, 2014, 20(40): 14934.

[11] Xu M, Chen Y, Artru F. Acute decompensation of cirrhosis versus acute‐on‐chronic liver failure: What are the clinical implications?[J]. United European Gastroenterology Journal, 2024, 12(2): 194-202.

[12] Choudhury A, Kulkarni A V, Arora V, et al. Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia[J]. Hepatology International, 2025, 19(1): 1-69.

[13] Arab J P, Martin-Mateos R M, Shah V H. Gut–liver axis, cirrhosis and portal hypertension: The chicken and the egg[J]. Hepatology international, 2018, 12(Suppl 1): 24-33.

[14] Simbrunner B, Mandorfer M, Trauner M, et al. Gut-liver axis signaling in portal hypertension[J]. World journal of gastroenterology, 2019, 25(39): 5897.

[15] Trebicka J, Reiberger T, Laleman W. Gut-liver axis links portal hypertension to acute-on-chronic liver failure[J]. Visceral medicine, 2018, 34(4): 270-275.

[16] Lin L, Zhang J. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases[J]. BMC immunology, 2017, 18(1): 2.

[17] Okumura R, Takeda K. Maintenance of intestinal homeostasis by mucosal barriers[J]. Inflammation and regeneration, 2018, 38(1): 5.

[18] Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis[J]. Experimental & molecular medicine, 2017, 49(5): e338-e338.

[19] Chopyk D M, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159(3): 849-863.

[20] Kayama H, Takeda K. Functions of innate immune cells and commensal bacteria in gut homeostasis[J]. The Journal of Biochemistry, 2016, 159(2): 141-149.

[21] Nicoletti A, Ponziani F R, Biolato M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World journal of Gastroenterology, 2019, 25(33): 4814.

[22] Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis[J]. World journal of gastroenterology: WJG, 2012, 18(21): 2609.

[23] Katsarou A, Moustakas I I, Pyrina I, et al. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease[J]. World journal of gastroenterology, 2020, 26(17): 1993.

[24] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. Journal of hepatology, 2021, 75: S49-S66.

[25] Kim S E, Park J W, Kim H S, et al. The role of gut dysbiosis in acute-on-chronic liver failure[J]. International journal of molecular sciences, 2021, 22(21): 11680.

[26] Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. Journal of hepatology, 2021, 75: S67-S81.

[27] Guohong-Liu, Qingxi-Zhao, Hongyun-Wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis[J]. Annals of Hepatology, 2019, 18(6): 796-803.

[28] Chen D, Le T H, Shahidipour H, et al. The role of gut-derived microbial antigens on liver fibrosis initiation and progression[J]. Cells, 2019, 8(11): 1324.

[29] Zhang T, Sun K, Wang Y, et al. Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure[J]. European journal of gastroenterology & hepatology, 2018, 30(2): 130-135.

[30] Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis[J]. World journal of gastroenterology: WJG, 2014, 20(45): 16795.

[31] Fan Y, Li Y, Chu Y, et al. Toll-like receptors recognize intestinal microbes in liver cirrhosis[J]. Frontiers in immunology, 2021, 12: 608498.

[32] Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?[J]. Expert review of gastroenterology & hepatology, 2015, 9(8): 1069-1076.

[33] Dirchwolf M, Ruf A E. Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis[J]. World journal of hepatology, 2015, 7(16): 1974.

[34] Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. Journal of hepatology, 2021, 74(3): 670-685.

[35] Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz A J, et al. Inflammatory status in human hepatic cirrhosis[J]. World journal of gastroenterology, 2015, 21(41): 11522.

[36] Clària J, Arroyo V, Moreau R. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure[J]. JHEP Reports, 2023, 5(9): 100807.

[37] Solé C, Solà E, Morales-Ruiz M, et al. Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis[J]. Scientific reports, 2016, 6(1): 32341.

[38] Premkumar M, Anand A C. Overview of complications in cirrhosis[J]. Journal of clinical and experimental hepatology, 2022, 12(4): 1150-1174.

[39] Romero-Gomez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure[J]. Journal of Hepatology, 2015, 62(2): 437-447.

[40] Khanam A, Kottilil S. Abnormal innate immunity in acute-on-chronic liver failure: immunotargets for therapeutics[J]. Frontiers in Immunology, 2020, 11: 2013.

[41] Triantafyllou E, Woollard K J, McPhail M J W, et al. The role of monocytes and macrophages in acute and acute-on-chronic liver failure[J]. Frontiers in immunology, 2018, 9: 2948.

[42] Xie D, Ouyang S. The role and mechanisms of macrophage polarization and hepatocyte pyroptosis in acute liver failure[J]. Frontiers in immunology, 2023, 14: 1279264.

[43] Casulleras M, Zhang I W, Lopez-Vicario C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9(12): 2632.

[44] Satsangi S, Duseja A, Sachdeva M, et al. Monocyte human leukocyte antigen–antigen D related, neutrophil oxidative burst and cytokine analysis in patients of decompensated cirrhosis with and without acute-on chronic liver failure[J]. PLoS One, 2018, 13(7): e0200644.

[45] Hasa E, Hartmann P, Schnabl B. Liver cirrhosis and immune dysfunction[J]. International immunology, 2022, 34(9): 455-466.

[46] Sipeki N, Antal-Szalmas P, Lakatos P L, et al. Immune dysfunction in cirrhosis[J]. World journal of gastroenterology: WJG, 2014, 20(10): 2564.

[47] Kou K, Sun X, Tian G, et al. The mechanisms of systemic inflammatory and immunosuppressive acute‐on‐chronic liver failure and application Prospect of single‐cell sequencing[J]. Journal of Immunology Research, 2022, 2022(1): 5091275.

[48] Tyc O, Shi Y, Fan Y C, et al. Acute-on-chronic liver failure: systemic inflammation and immunosuppression[J]. Frontiers in Immunology, 2023, 14: 1260749.

[49] Ye C, Li W, Li L, et al. Glucocorticoid treatment strategies in liver failure[J]. Frontiers in Immunology, 2022, 13: 846091.

[50] Xue R, Meng Q. The management of glucocorticoid therapy in liver failure[J]. Frontiers in immunology, 2019, 10: 2490.

[51] Engelmann C, Adebayo D, Oria M, et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure[J]. Scientific Reports, 2020, 10(1): 389.

[52] Mao X, Hu X, Fang J. Gut microbiota-metabolite interactions in drug-induced liver injury: mechanisms, biomarkers, and therapeutic perspectives[J]. Frontiers in Cellular and Infection Microbiology, 2025, 15: 1737234.

[53] Kumar R, Mehta G, Jalan R. Acute-on-chronic liver failure[J]. Clinical Medicine, 2020, 20(5): 501-504.

[54] Asrani S K, Simonetto D A, Kamath P S. Acute-on-chronic liver failure[J]. Clinical gastroenterology and hepatology, 2015, 13(12): 2128-2139.